BAFF stands for B-cell activating factor, a crucial protein cytokine in the tumor necrosis factor (TNF) superfamily that promotes B-cell maturation, survival, and immunoglobulin production.
B-cell activating factor is a protein (a cytokine) that helps regulate B cell survival, maturation, and antibody production.
BAFF promotes survival of mature B cells by blocking apoptosis and supports B-cell responses.
BAFF (B-cell Activating Factor) also called BLyS (B Lymphocyte Stimulator), is a TNF superfamily cytokine (TNFSF13B) that functions as a critical B-cell survival and differentiation factor.
BAFF acts primarily on **B cells** through receptors such as **BAFF-R (BR3), TACI, and BCMA.
Dysregulation of BAFF is heavily implicated in autoimmune diseases, making it a major therapeutic target.
BAFF functions as a fundamental survival factor for B cells, controlling the size and composition of pre-immune B-cell pools.
Receptors: BAFF binds to three distinct receptors expressed on B cells: BAFF-R, TACI, and BCMA.
Signaling: When BAFF binds to its primary receptor (BAFF-R), it activates the NF-kB signaling pathway, which is vital for B-cell expansion and survival.
Cell Types: While primarily known for its role in B-cell physiology, it also supports monocyte survival, activation, and differentiation into macrophages.
Because of its role in governing immune cell survival, BAFF is a critical player in both health and pathology:
Autoimmune Diseases: Elevated serum levels of BAFF are strongly associated with autoimmune disorders where the immune system attacks healthy tissue.
These include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS).
Immunological Targets: Because blocking BAFF signaling helps control the survival and expansion of rogue autoimmune B cells, BAFF has become a major focal point for targeted biopharmaceuticals and modulators.
BAFF is produced by: myeloid cells (monocytes, macrophages, DCs), T cells, stromal cells, epithelium.
BAF Receptor:
BAFFR— B-cell specific; primary driver of mature B-cell survival TACI— shared with APRIL; expressed on B cells and myeloid cells; regulates Ig class switching and plasma cell function BCMA— shared with APRIL(A proliferation reducing, inducing ligand); preferentially expressed on plasma cells/long-lived plasma cells (LLPCs)
Promotes B-cell maturation from transitional → mature naïve, prevents deletion of autoreactive clones, sustains LLPCs and memory B cells.
SLE- Overexpressed; sustains autoreactive B cells; correlates with renal involvement.
IgA Nephropathy-Drives galactose-deficient IgA1 production via B-cell dysregulation.
CVIDElevated BAFF:TACI ratio → autoimmune/lymphoproliferative complications.
Multiple Myeloma-Survival factor for malignant plasma cells via NF-κB; inversely correlates with OS
ITP Upregulated BAFF-R/TACI on autoreactive lymphocytes drives hyperreactivity.
B cells play a key role in the pathophysiology of primary ITP.
The B cell activating factor (BAFF) signaling pathway is crucial for B cell proliferation, differentiation, and survival.
Serum BAFF levels are increased in patients with untreated ITP, highlighting, BAFF and its receptor as promising therapeutic targets.
COPD-Overexpressed in lymphoid follicles; correlates with disease severity
Autoimmune Hepatitis-Elevated BAFF predicts poor treatment response.
Therapeutic Targeting
Belimumab (Benlysta)-Anti-BAFF mAb; FDA-approved for SLE and lupus nephritis.
Telitacicept-TACI-Fc fusion; dual BAFF + APRIL blockade; studied in SLE, IgAN, others.
Rituximab paradox:RTX-mediated B-cell depletion reflexively increases BAFF levels → rationale for RTX + belimumab combination strategies.
BCMA-directed CAR-T: Targets downstream BAFF/APRIL-dependent LLPCs; showing efficacy in refractory autoimmune disease.
BAFF neutralization in the atherosclerosis context may be pro-atherogenic via a B-cell-independent macrophage/TACI pathway — a potential safety signal relevant for long-term belimumab use in high-CV-risk patients
Too much BAFF activity can contribute to autoimmune diseases where self-reactive B cells persist (e.g., some cases of rheumatoid arthritis and lupus).
Drugs that **neutralize BAFF/BLyS** or block its signaling are used in certain B-cell–driven conditions.
Place on site